Clozapine vs olanzapine: when each one wins

Clozapine and olanzapine are chemical cousins. Both are tricyclic atypical antipsychotics, both bind a wide spectrum of receptors, and both can cause significant weight gain. Yet in clinical practice they sit in very different places: olanzapine is a common first- or second-line option, while clozapine is reserved for people whose symptoms have not responded to other medications. This guide is for patients, families, and clinicians thinking through which one — if either — makes sense in a given situation. It is a decision aid, not a recommendation.

The shared chemistry

Both drugs are derived from the same dibenzodiazepine/thienobenzodiazepine scaffold. Both block multiple receptor systems — D2, 5-HT2A, H1, M1, and alpha-1 adrenergic — which is why they share so many side effects (sedation, weight gain, dry mouth, orthostatic dizziness). But clozapine has unusually weak D2 binding compared with olanzapine, plus stronger effects at additional receptor sites that may explain its unique efficacy in treatment-resistant illness.

What the major trials show

The clearest comparison comes from the CATIE trial (NIMH-funded, published in NEJM in 2005), which followed roughly 1,500 patients with chronic schizophrenia for 18 months. Olanzapine had the longest time-to-discontinuation among the first-phase atypicals — meaning patients stayed on it longer than on quetiapine, risperidone, ziprasidone, or perphenazine. In the second phase, for patients who had failed an initial atypical, clozapine outperformed every other option on time-to-discontinuation by a meaningful margin.

The British CUtLASS-2 trial reached the same conclusion in a different population: in patients whose symptoms had not responded to at least two prior antipsychotics, clozapine produced significantly better symptom and quality-of-life outcomes than other second-generation drugs over 12 months. NIMH summaries of these findings are available at nimh.nih.gov.

Efficacy head-to-head

For first-episode and non-resistant schizophrenia, network meta-analyses (Leucht et al., Lancet 2013; available via PubMed) place olanzapine and clozapine at the top of the efficacy rankings, with olanzapine slightly behind clozapine but ahead of most other agents. In treatment-resistant schizophrenia (defined as inadequate response to two adequate antipsychotic trials), the gap widens substantially — clozapine's response rate is roughly 30–60% in patients who had not responded to anything else.

Clozapine is also the only antipsychotic with an FDA indication for reducing suicidal behaviour in schizophrenia and schizoaffective disorder, based on the InterSePT trial. No comparable indication exists for olanzapine.

Side effects: the trade-offs

Weight and metabolic burden

Both are among the heaviest hitters on metabolic side effects. Average weight gain in the first year is roughly 5–8 kg with olanzapine and 8–12 kg with clozapine, with substantial variation between individuals. Both meaningfully raise the risk of type 2 diabetes and dyslipidaemia. The American Diabetes Association consensus statement applies to both. See our weight gain management guide and metabolic syndrome explainer.

Sedation

Both are sedating, with clozapine generally more so, particularly during titration.

Movement and prolactin

Both have low rates of extrapyramidal symptoms and minimal prolactin elevation — strong points relative to risperidone or first-generation drugs.

Clozapine-specific risks

• Severe neutropenia (lifetime risk ~0.4–1%), the reason for the Clozapine REMS mandatory blood monitoring program
• Myocarditis, typically in the first 4–8 weeks
• Severe constipation and ileus
• Hypersalivation, particularly at night
• Seizures, dose-related

Olanzapine-specific notes

Olanzapine LAI (Zyprexa Relprevv) carries a small risk of post-injection delirium/sedation syndrome and requires three hours of clinical observation after each dose — a logistic burden that limits its use.

Monitoring intensity

Olanzapine requires baseline and periodic metabolic labs. Clozapine adds weekly absolute neutrophil counts for the first 6 months, then biweekly for 6 months, then monthly indefinitely, plus baseline and follow-up ECG and cardiac monitoring during the first weeks. For some patients this is acceptable; for others, the logistical burden is the reason they never start.

When clozapine is the better choice

• Documented inadequate response to two prior antipsychotics at adequate dose and duration
• Persistent suicidality in schizophrenia or schizoaffective disorder
• Severe symptoms despite olanzapine at maximally tolerated dose
• Persistent aggression that hasn't responded to other treatments

When olanzapine is the better choice

• First or second antipsychotic trial
• Need for rapid stabilisation (e.g., acute mania)
• Patient unable or unwilling to complete weekly bloodwork
• Lower acute cardiovascular risk during titration

The under-prescription problem

Surveys repeatedly find that clozapine is prescribed to roughly 5% of US patients with schizophrenia, compared to 20–30% in some European countries. Many people who would benefit are kept on less effective regimens because of monitoring logistics, prescriber discomfort, or inadequate insurance support. See our piece on why clozapine remains under-used.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.